PRESTIGE CONSUMER HEALTHCARE INC. (PBH) Gross Margin
- Gross margin · 12 months: Value 53.53%; Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | 53.53% | Gross profit / revenue. Period ending 2026-06-30. $591.43M ÷ $1.10B × 100 ≈ 53.53% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | 591.43M USD | Gross Profit |
| Revenue | 1.10B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | $591.43M | $1.10B | (m) | 53.53% |
| 2026-03-31 | $595.58M | $1.09B | (m) | 54.71% |
| 2025-12-31 | $619.29M | $1.10B | (m) | 56.12% |
| 2025-09-30 | $622.97M | $1.11B | (m) | 56.10% |
| 2025-06-30 | $628.77M | $1.12B | (m) | 56.13% |
| 2025-03-31 | $634.46M | $1.14B | (m) | 55.76% |
| 2024-12-31 | $616.27M | $1.12B | (m) | 55.11% |
| 2024-09-30 | $613.16M | $1.11B | (m) | 55.21% |
| 2024-06-30 | $615.80M | $1.11B | (m) | 55.32% |
| 2024-03-31 | $624.45M | $1.13B | (m) | 55.49% |
| 2023-12-31 | $626.39M | $1.13B | (m) | 55.23% |
| 2023-09-30 | $618.86M | $1.13B | (m) | 54.91% |
| 2023-06-30 | $619.85M | $1.13B | (m) | 54.86% |
| 2023-03-31 | $625.29M | $1.13B | (m) | 55.45% |
| 2022-12-31 | $620.39M | $1.11B | (m) | 55.95% |
| 2022-09-30 | $625.05M | $1.11B | (m) | 56.43% |
| 2022-06-30 | $621.75M | $1.09B | (m) | 56.80% |
| 2022-03-31 | $620.65M | $1.09B | (m) | 57.11% |
| 2021-12-31 | $608.84M | $1.06B | (m) | 57.57% |
| 2021-09-30 | $592.67M | $1.02B | (m) | 57.99% |
| 2021-06-30 | $572.62M | $983.15M | (m) | 58.24% |
| 2021-03-31 | $547.47M | $943.37M | (m) | 58.03% |
| 2020-12-31 | $554.33M | $956.84M | (m) | 57.93% |
| 2020-09-30 | $552.93M | $959.60M | (m) | 57.62% |
| 2020-06-30 | $552.02M | $960.25M | (m) | 57.49% |
| 2020-03-31 | $552.22M | $963.01M | (m) | 57.34% |
| 2019-12-31 | $546.56M | $952.80M | (m) | 57.36% |
| 2019-09-30 | $548.30M | $952.66M | (m) | 57.55% |
| 2019-06-30 | $549.02M | $953.95M | (m) | 57.55% |
| 2019-03-31 | $555.58M | $975.78M | (m) | 56.94% |
| 2018-12-31 | $558.59M | $990.72M | (m) | 56.38% |
| 2018-09-30 | $567.03M | $1.02B | (m) | 55.60% |
| 2018-06-30 | $573.65M | $1.04B | (m) | 55.23% |
| 2018-03-31 | $576.50M | $1.04B | (m) | 55.37% |
| 2017-12-31 | $565.43M | $1.03B | (m) | 55.12% |
| 2017-09-30 | $542.30M | $972.03M | (m) | 55.79% |
| 2017-06-30 | $522.17M | $929.06M | (m) | 56.20% |
| 2017-03-31 | $500.29M | $882.06M | (m) | 56.72% |
| 2016-12-31 | $488.35M | $849.25M | (m) | 57.50% |
| 2016-09-30 | $480.59M | $832.68M | (m) | 57.72% |
| 2016-06-30 | $476.57M | $823.69M | (m) | 57.86% |
| 2016-03-31 | $467.21M | $806.25M | (m) | 57.95% |
| 2015-12-31 | $459.03M | (m) | (m) | (m) |
| 2015-09-30 | $453.99M | (m) | (m) | (m) |
| 2015-06-30 | $436.59M | (m) | (m) | (m) |
| 2015-03-31 | $406.22M | (m) | (m) | (m) |
| 2014-12-31 | $379.49M | $672.13M | (m) | 56.46% |
| 2014-09-30 | $348.21M | $619.39M | (m) | 56.22% |
| 2014-06-30 | $338.89M | $605.07M | (m) | 56.01% |
| 2014-03-31 | $340.05M | $601.88M | (m) | 56.50% |
| 2013-12-31 | $348.08M | $612.14M | (m) | 56.86% |
| 2013-09-30 | $351.27M | $626.16M | (m) | 56.10% |
| 2013-06-30 | $347.10M | $619.57M | (m) | 56.02% |
| 2013-03-31 | $347.22M | $623.60M | (m) | 55.68% |
| 2012-12-31 | $327.63M | $603.08M | (m) | 54.33% |
| 2012-09-30 | $297.76M | $549.10M | (m) | 54.23% |
| 2012-06-30 | $261.12M | $492.79M | (m) | 52.99% |
| 2012-03-31 | $227.38M | $441.08M | (m) | 51.55% |
| 2011-12-31 | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) |
| 2011-03-31 | $170.88M | $336.51M | (m) | 50.78% |
| 2010-12-31 | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) |
| 2010-03-31 | $153.44M | $292.60M | (m) | 52.44% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |